Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Rakuten Medical CEO-Elect Reaffirms 2028 US Filing Plan for Akalux
Minami Maeda, who will become CEO of Rakuten Medical’s US headquarters on July 1, says his immediate priority is to secure a US filing in 2028 for ASP-1929, the company’s lead photoimmunotherapy asset marketed in Japan as Akalux. Speaking to…
To read the full story
Related Article
- Rakuten Medical to Promote President Maeda to CEO
June 11, 2026
- Rakuten Ramps Up Photoimmunotherapy PIII with Financing, Eyes US Filing in 2028
January 9, 2026
- Rakuten Launches Japan Arm of Global PIII for Photoimmunotherapy/Keytruda Combo
July 30, 2025
- Rakuten Medical Launches Global PIII Trial of Photoimmunotherapy/Keytruda Combo
January 27, 2025
- Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
BUSINESS
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
- Nipro Grabs Japan Approval for Stelara IV Biosimilar
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…